Details for New Drug Application (NDA): 212955
✉ Email this page to a colleague
NDA 212955 describes NALMEFENE HYDROCHLORIDE, which is a drug marketed by Chengdu Shuode and Knoa Pharma and is included in two NDAs. It is available from two suppliers. Additional details are available on the NALMEFENE HYDROCHLORIDE profile page.
The generic ingredient in NALMEFENE HYDROCHLORIDE is nalmefene hydrochloride. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the nalmefene hydrochloride profile page.
The generic ingredient in NALMEFENE HYDROCHLORIDE is nalmefene hydrochloride. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the nalmefene hydrochloride profile page.
Summary for 212955
| Tradename: | NALMEFENE HYDROCHLORIDE |
| Applicant: | Knoa Pharma |
| Ingredient: | nalmefene hydrochloride |
| Patents: | 0 |
Pharmacology for NDA: 212955
| Mechanism of Action | Opioid Antagonists |
Suppliers and Packaging for NDA: 212955
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| NALMEFENE HYDROCHLORIDE | nalmefene hydrochloride | SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | 212955 | ANDA | Knoa Pharma LLC | 59011-960 | 59011-960-10 | 10 VIAL, GLASS in 1 CARTON (59011-960-10) / 2 mL in 1 VIAL, GLASS |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | Strength | EQ 2MG BASE/2ML (EQ 1MG BASE/ML) | ||||
| Approval Date: | Feb 8, 2022 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
